← Leaderboards
Timothy R Siegert
Allyx Biosciences, Inc.
$5,817,445
Attributed
$5,817,445
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,817,445 · 3
By mechanism
SB1$3,347,703 · 1
R44$2,469,742 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposFunctional DisorderAbeta OligomerDisease ProgressionFormulationAmyloid Beta-ProteinCommercial ApplicationCommercializationDementiaDensityClinical ResearchDrug KineticsBiological Response ModifiersBiotechnologyComplexCognitionCapsuleCaregiversCause Of DeathCensusesBindingDementia CareDoseGenetic
Grant awards (5)
Clinical evaluation of BMS-984923 metabolism.$1,669,100
SB1 · FY2025 · AG · contact PI
Clinical evaluation of BMS-984923 metabolism.$1,678,603
SB1 · FY2024 · AG · contact PI
BMS-984923 Non-Clinical Development to Support Phase 2 Trials$1,339,527
R44 · FY2023 · AG · contact PI
BMS-984923 Non-Clinical Development to Support Phase 2 Trials$680,220
R44 · FY2022 · AG · contact PI
Cellular Prion Protein Targeting Monoclonal Antibody Antagonist as a Therapy for Alzheimer's Disease$449,995
R44 · FY2020 · AG · contact PI